1. Home
  2. CSTL vs MCB Comparison

CSTL vs MCB Comparison

Compare CSTL & MCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSTL
  • MCB
  • Stock Information
  • Founded
  • CSTL 2007
  • MCB 1999
  • Country
  • CSTL United States
  • MCB United States
  • Employees
  • CSTL N/A
  • MCB N/A
  • Industry
  • CSTL Medical Specialities
  • MCB Major Banks
  • Sector
  • CSTL Health Care
  • MCB Finance
  • Exchange
  • CSTL Nasdaq
  • MCB Nasdaq
  • Market Cap
  • CSTL 697.9M
  • MCB 694.8M
  • IPO Year
  • CSTL 2019
  • MCB 2017
  • Fundamental
  • Price
  • CSTL $21.62
  • MCB $78.95
  • Analyst Decision
  • CSTL Strong Buy
  • MCB Buy
  • Analyst Count
  • CSTL 6
  • MCB 2
  • Target Price
  • CSTL $37.67
  • MCB $84.50
  • AVG Volume (30 Days)
  • CSTL 423.4K
  • MCB 72.2K
  • Earning Date
  • CSTL 11-03-2025
  • MCB 10-16-2025
  • Dividend Yield
  • CSTL N/A
  • MCB 0.77%
  • EPS Growth
  • CSTL N/A
  • MCB N/A
  • EPS
  • CSTL N/A
  • MCB 6.17
  • Revenue
  • CSTL $346,269,000.00
  • MCB $274,307,000.00
  • Revenue This Year
  • CSTL N/A
  • MCB $13.56
  • Revenue Next Year
  • CSTL N/A
  • MCB $11.39
  • P/E Ratio
  • CSTL N/A
  • MCB $12.71
  • Revenue Growth
  • CSTL 20.40
  • MCB 10.33
  • 52 Week Low
  • CSTL $14.59
  • MCB $47.08
  • 52 Week High
  • CSTL $35.84
  • MCB $81.33
  • Technical
  • Relative Strength Index (RSI)
  • CSTL 50.19
  • MCB 59.21
  • Support Level
  • CSTL $22.54
  • MCB $75.95
  • Resistance Level
  • CSTL $24.74
  • MCB $80.49
  • Average True Range (ATR)
  • CSTL 1.14
  • MCB 1.89
  • MACD
  • CSTL -0.28
  • MCB -0.20
  • Stochastic Oscillator
  • CSTL 28.93
  • MCB 55.76

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

About MCB Metropolitan Bank Holding Corp.

Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.

Share on Social Networks: